Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 7/20 | 0.44 |
| ▸ | PRKCA | P17252 | 4/20 | 0.44 |
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | PRKCB | P05771 | 1/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 9/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8967129 | 0.84 | FLT3 (0.47) | PRKCQPRKCAFLT3PRKCBPRKCE | |
| SCHEMBL8967043 | 0.84 | PRKCQ (0.49) | PRKCQPRKCAFLT3PRKCBPRKCE | |
| SCHEMBL8967433 | 0.83 | IRAK4 (0.47) | PRKCQPRKCAFLT3PRKCBPRKCE | |
| SCHEMBL8967048 | 0.82 | PRKCQ (0.48) | PRKCQPRKCAFLT3PRKCBPRKCE | |
| SCHEMBL8968121 | 0.79 | PRKCQ (0.46) | PRKCQPRKCAFLT3PRKCBPRKCE | |
| SCHEMBL8967673 | 0.78 | PRKCQ (0.44) | PRKCQPRKCAFLT3PRKCBPRKCE | |
| SCHEMBL9012942 | 0.75 | PRKCQ (0.46) | PRKCQPRKCAFLT3PRKCBPRKCE | |
| SCHEMBL8967069 | 0.75 | PRKCQ (0.54) | PRKCQPRKCAFLT3PRKCBPRKCE | |
| SCHEMBL8967013 | 0.74 | PRKCQ (0.47) | PRKCQPRKCAFLT3PRKCBPRKCE | |
| SCHEMBL8967647 | 0.74 | PRKCQ (0.47) | PRKCQPRKCAFLT3PRKCBPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815866-B2 | Aminopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815866-B2 | Aminopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-20130137703-A1 | AMINOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137703-A1 | AMINOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-30 | — | — | US | disclosed |
| US-8377926-B2 | Aminopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377926-B2 | Aminopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCQ 38/4885PRKCA 25/4885FLT3 330/4885 |
| US-20120214799-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCQ 38/4885PRKCA 25/4885FLT3 330/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCQ 38/4885PRKCA 25/4885FLT3 330/4885 |
| US-20130137703-A1 | AMINOPYRIDINE KINASE INHIBITORS | MAP3K5, MAP3K20, MAP4K5 | PRKCQ 37/4885PRKCA 24/4885FLT3 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.